{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-107988","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.257321+00:00","generated_at":"2026-05-31T03:40:07.216126+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1","bullets":["Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.","At 1E9 dose, 27-64% of total cellular material in evaluable biopsies, exceeding published autologous alpha-beta CAR T levels.","Complete CD19+ B cell depletion observed in secondary lymphoid tissue concurrent with trafficking and activation.","Data highlight potential best-in-class profile vs. anti-CD20 antibodies that failed to deplete B cells in tissues.","Initial clinical data from autoimmune programs (lupus nephritis, SLE, systemic sclerosis, AAV) expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-107988","json":"https://secwatch.observer/filing/0000950170-24-107988.json","markdown":"https://secwatch.observer/filing/0000950170-24-107988.md","text":"https://secwatch.observer/filing/0000950170-24-107988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/0000950170-24-107988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/acet-20240919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:40:07.216126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}